The approval and reimbursement of selpercatinib for RET-positive advanced NSCLC was supported by comparing trial data against RWE from databases like Flatiron Health . 3. Evaluating Quality of Care
As lung cancer is increasingly redefined by specific genetic mutations (e.g., ROS1, RET, NTRK fusions), patient subgroups become extremely small—sometimes representing only 1% of cases.
Real-world evidence refers to clinical evidence derived from the analysis of , which is collected from sources outside of traditional highly-controlled randomized clinical trials (RCTs). These sources include electronic health records, insurance claims, and product/disease registries. 1. Addressing Gaps in Clinical Trials (629 KB)
In cases where randomized trials are impossible due to small patient populations, RWE has been used to supplement single-arm trials for drug approvals.
Traditional clinical trials often exclude "real-world" patients, such as: Real-world evidence refers to clinical evidence derived from
The reference (kilobytes) is most commonly associated with a specific scholarly review regarding the use of Real-World Evidence (RWE) in the management of lung cancer, published in the journal Current Oncology . Real-World Evidence in Lung Cancer Management
Research identifying a "gene desert" region upstream of the MYC gene (extending up to 629 Kb) which contains risk factors for cancers like Chronic Lymphocytic Leukemia (CLL). Addressing Gaps in Clinical Trials In cases where
Often defined as those over 70, who are frequently under-represented in trials but common in clinical practice.